Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1993-09-15
2000-07-04
Minnifield, Nita
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
424 851, 424 852, 514903, 514825, 514885, 514125, 436506, A61K 3900, A61K 4505, A61K 3166, A01N 5700
Patent
active
060835036
ABSTRACT:
A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes. Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals, or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as to cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of autoimmune diseases such as, for example, multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, autoimmune myocarditis, etc., allergic disorders such as hay fever, extrinsic asthma, or insect bite and sting allergies, food and drug allergies, as well as for the treatment or prevention of graft rejection.
REFERENCES:
patent: 4469677 (1984-09-01), Michael et al.
patent: 4904481 (1990-02-01), Fathman
patent: 5260422 (1993-11-01), Clark et al.
BioWorld Today 8(77):1-4, see pp. 1 and 3 "AutoImmune Stock Sinks on Disappointing Phase III Myloral Trial Data in MS", Apr. 22, 1997.
Coates, A., et al., "Immune Protection Against Experimental Autoimmune Encephalomylelitis: Optimal Conditions and Analysis of Mechanism," Cellular Immunology, 12:370-381 (1974).
Alvord, E.C., Jr., et al., "Encephalitogen-Induced Inhibition of Experimental Allergic Encephalomyelitis: Prevention, Suppression and Therapy," Annals N.Y. Acad. Sci., 122:333-345 (1965).
Rauch, H.C., "Short Communications: Modulation of Adoptive Cell Transfers in Experimental Allergic Encephalomyelitis by Antigen Treatment of Donors," Cellular Immunology, 60:220-227 (1981).
Raine, C.S., et al., "Suppression of Chronic Allergic Encephalomyelitis: Relevance to Multiple Sclerosis," Science, 201 (4354): 445-448 (1978).
Moller, G., "Do Suppressor T Cells Exist?", Scand. J. Immunol., 27: 247-250 (1988).
Gonsette, R.E., et al., "Failure of Basic Protein Therapy for Multiple Sclerosis," J. Neurol., 216:27-31 (1977).
Einstein, E.R., et al., "Protective Action of the Encephalitogen and Other Basic Proteins in Experimental Allergic Encephalomyelitis," Immunochemistry, 5:567-575 (1968).
Shaw, C., et al., "Suppression of Experimental `Allergic` Encephalomyelitis in Guinea Pigs by Encephalitogenic Proteins Extracted from Homologous Brain," J. Ex. Med., 160:171-180 (1960).
Eylar, E.H., et al., "Suppression of the Immune Response: Reversal of the Disease State with Antigen in Allergic Encephalomyelitis," Nature, 236:74-76 (Mar. 10, 1972).
Cunningham, V.R., et al., "Experimental Allergic Encephalomyelitis: Protection Experiments with Encephalitogenic Factor and Tubercle Fractions," Annals N.Y. Acad. Sci., 122:346-355 (1965).
Lenardo, Michael J. (1991) "Interleukin-2 programs mouse .alpha..beta. T lymphocytes for apoptosis", Nature, 353:858-861.
Marx, Jean (1991) "Testing of Autoimmune Therapy Begins", Science, 252:27-28.
Sambhara, S., et al. (1991) "Programmed Cell Death of T Cells Signaled by the T Cell Receptor and the .alpha..sub.3 Domain of Class I MHC", Science, 252:1424-1427.
Hemler, Martin E., et al. (1984) "Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells", Proc. Natl. Acad. Sci., 81:2172-2175.
Lotze, Michael T., et al. (1985) "In Vivo Administration of Purified Human Interleukin 2", The Journal of Immunology, 135:2865-2875.
Roitt, Ivan M. (1988) Essential Immunology, Blackwell Scientific Publications, Oxford, 195-200.
Roitt, Ivan M., et al. (1985) Immunology, Gower Medical Publishing, London, p. 24.3.
Bitar, et al., Cellular Immunology, 112: 364-370 (1988).
Higgins, et al., The Journal of Immunology, vol. 140: 440-445, No. 2 (1988).
Nussenblatt, et al, The Journal of Immunology, vol. 144: 1689-1695, No. 5 (1990).
Waksman and Reynolds. Proc. Soc. Exp. Biol. Med 175:282-94 1984.
Russell et al. (1991) Proc. Natl. Acad. Sci. 88:2151-2155.
Liu et al. (1990) J. Exp. Med. 172:1735-1739.
Jones et al. (1990) Science 250:1726-1729.
Webb et al. (1990) Cell 63:1249-1256.
U.S. Pharmacopeial Convention Update (1992) 1:656.
Drug Interactions & Side Effects Index (1992) 46th Edition.
Ashwell et al. (1987) Journal of Exper. Medicine 165:173-194.
O'Brien et al. (1991) Seminars in Immunology 3:81-87.
Crabtree (1989) Science 243:355-361.
Paul (1989) Fundamental Immunology, 2nd Edition, Raven Press, NY pp. 804, 876-878, 898-902, 291-313, 10.
Kang et al. (1992) Science 257:1134-1138.
Allison (1991) Seminars in Immunology 3:73-74.
Havran et al. (1991) Seminars in Immunology 3:89-97.
Matzinger et al. (1989) Nature 338:74-76.
Sussman et al. (1988) Cell 52:85-95.
Rocha et al. (1991) Science 251:1225-1228.
Rellahan et al. (1990) Journal of Exper. Medicine 172:1091-1100.
Veterinary Pharmaceuticals & Biologicals (1990) Sixth Edition pp. 506, 543.
R. Patterson (1990) Allergic Diseases Diagnosis and Management JB Lippincott Co., Philadelphia, pp. 1-13, 17-21, & 52-57.
Cruse et al. (1992) in J. Cruse et al., ads., Clinical and Molecular Aspects of Autoimmune Disease, Karger, Basel, 1-17.
Lo, Research in Immunology, (1992), No. 3, vol. 143:296-299.
Kroemer et al., Research in Immunology (1992) No. 3 vol. 143:335-40.
Mercep et al., Science (1989) 246:1162-1165.
White et al. The VB Specific Superantigen Staphylococcal . . . Cell 56 pp. 27-35 1989.
Pelliard et al. Evidence for the Effects of a Superantigen in . . . Science pp. 325-329 Jul. 1991.
Ucker et al. Requirements for De Novo Transcription and Translation . . . J. of Immunol. 3461-69 1989.
Nau et al. Inhibition of IL-2 . . . J. of Immunol. 139:114-122 (1987).
Jansenn et al. T-cell Receptor/CDS Signaling . . . J. Immunol. 146:35-39 1991.
Wraith et al., (1989) Cell, 59:247-255.
Kawabe et al., (1991) Letters to Nature, 349:245-248.
McConkey et al. (1990) Immunology Today, 11(4):120-121.
Russell et al., (1991) Proc. Natl. Acad. Sci. USA 88:2151-2155.
M. Kronenberg (1991) Cell, 65:537-542.
Eylar et al. Neurochemical Research 4: 249-258, 1979.
Plotkin, S.A. et al. "Vaccines", published by U.B. Spunders Company, see p. 571, 1988.
Minnifield Nita
The United States of America as represented by the Department of
LandOfFree
Interleukin-2 stimulated T lymphocyte cell death for the treatme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-2 stimulated T lymphocyte cell death for the treatme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-2 stimulated T lymphocyte cell death for the treatme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1483449